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ABSTRACT 
 
OBJECTIVES: The objective of this selective EBM review is to determine whether or not 
radioembolization is safer treatment comparing to chemoembolization in patients with primary 
liver cancer (HCC) 
 
STUDY DESIGN: Review of three English language primary randomized controlled studies 
published between 2014 and 2016.  
 
DATA SOURCES: Three randomized controlled trials (RCT) were found using PubMed and 
Medline database. 
 
OUTCOMES MEASURED: Eligible patients were randomly selected and divided into two 
groups: one group received radioembolization with Y-90 (TARE Y-90) while the other group 
received chemoembolization (TACE). Adverse events after post treatment were recorded and 
compared between TARE Y-90 and TACE 
 
RESULTS: The study by El Fouly et al. (2014) found that less adverse events occurred in 
patients receiving TARE Y-90 comparing to patients receiving TACE. The study by Kolligs et 
al. (2015) found that gastrointestinal (GI) adverse events were more common in TARE Y-90 
treatment group than TACE treatment group. Overall, the results from Kolligs et al. study 
showed no significant difference of adverse events between TARE Y-90 and TACE group. The 
study by Salem et al. (2016) also found that the frequency of adverse events in both TARE Y-90 
and TACE group was similar. 
 
CONCLUSIONS: Results from two randomized controlled trials demonstrate that both TARE 
Y-90 and TACE could cause similar adverse events in HCC patients.  The third randomized 
controlled trial indicate that TARE Y-90 is superior than TACE regarding safety. 
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INTRODUCTION 
 
Primary liver cancer is a form of cancer that originates in the cells of the liver. 
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer. It accounts 
for 85% to 90% of all primary liver cases. 1 HCC is considered as the fifth most common cancer 
with over half a million new cases diagnosed annually worldwide.8 According to the World 
Health Organization, HCC is the second leading cause of cancer related mortality in the world.4 
“Most HCC cases (>80%) occur in either sub-Saharan Africa and in Eastern Asia”. 2 Over the 
past two decades, the incidence and prevalence of HCC have significantly increased in the 
United States.  There are approximately 20,000 new cases diagnosed in the United States each 
year. 6 HCC creates a heavy economic burden on the patients and society. In order to manage the 
20,000 new cases, it would roughly cost one billion U.S dollars not including morbidity and 
mortality cost. 6 In the United States, the incidence of HCC is two times higher in Asians and 
African Americans compared to Caucasian. 2,8 “During recent years as incidence rate increased 
the age distribution of HCC patients has shifted toward relatively younger ages, with the greatest 
proportional increases between ages 45 and 60”. 2 HCC is more commonly seen in males than 
females with a ratio of 2:1 due to the greater risk of hepatitis B virus (HBV) and hepatitis C virus 
(HCV) infection as well as higher alcohol consumption and tobacco use .2,8 
The exact causes of HCC are still unknown due to the complexity of the disease. 
However, there are several risk factors associated with the development of HCC including 
cirrhosis, HBV infection, HCV infection, alcoholic liver disease, nonalcoholic steatohepatitis 
(NASH), aflatoxin-contaminated food intake, diabetes, and obesity. 9 Major risk factors of HCC 
vary based on the region. Worldwide, chronic infection of HBV and HCV are known as the most 
common risk factors for developing HCC. 8 In the United States, the incidence of HCC caused 
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by HCV is much higher than HBV. 2 The pathophysiology of developing HCC varies based on 
the etiology. In chronic infection of HBV or HCV, the viral damage to the hepatocytes causes 
chronic inflammation, hepatocyte proliferation, fibrosis, cirrhosis, and eventually leads to liver 
cancer. 9 
During the early stages of HCC, patients may present asymptomatically with no physical 
signs due to the ability of the liver to regenerate its damaged tissues. Thus, a majority of patients 
with HCC are diagnosed when the disease has already progressed into advanced stages. 
“Between 90-95% of HCC patients will present with the triad of right upper quadrant pain, 
palpable mass, and weight loss”. 10 Other common signs and symptoms of HCC include pruritus, 
fever, early satiety, nausea, and vomiting. Abdominal pain is reported to be one of the most 
common symptoms of HCC primarily due to the visceral involvement of the abdominal or pelvic 
region. 10 On the physical exams, patients with an advanced stage of HCC will typically present 
with palpable liver masses, nodular liver, hepatic bruits, ascites, splenomegaly, jaundice, or 
peripheral edema.  
Several different diagnostic tools can be performed to detect HCC including blood tests, 
imaging studies, biopsy, and genetic tests. Blood tests are used to assess the liver functions and 
the serum level of alpha fetoprotein (AFP), a key tumor marker of HCC.  The serum marker AFP 
is highly sensitive, but it has a low specificity. Thus, blood tests should not be used alone as a 
diagnostic tool for HCC. According to the American Association for the Study of Liver Diseases 
(AASLD) guidelines, imaging studies should be obtained in conjunction with blood tests. 7 
Ultrasound (US) is often the first diagnostic test of choice because it is a low cost, non-invasive 
test with no radiation exposure to the patients. However, one of the disadvantages of US is that 
“the reliability is influenced by the expertise of the operator as well as the provision of dedicated 
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equipment”. 9 In addition, sensitivity and specificity of US are limited by the size of the tumors. 
US is best used to detect 80%-95% of tumors with 3-5 cm in diameter and 60%-80% of tumors 
<1 cm in diameter. 7,9 Thus, multiple phase computed tomography (CT) or magnetic resonance 
imaging (MRI) are subsequently performed to further evaluate and confirm the disease. 7  
Treatments of HCC are determined based on multiple factors such as patient performance 
status, stage of the disease, and liver reserve function. For early stage of HCC, liver 
transplantation and hepatic resection are the definitive treatments. 7 Ablative techniques such as 
radiofrequency ablation or cryotherapy are also considered as potential curative treatments of 
HCC. However, ablative techniques offer best efficacy only when the maximum diameter of the 
tumors is less than 3 cm. 7 Patients with cirrhosis and advanced stage of HCC are not eligible for 
liver transplantation, hepatic resection, or ablative techniques due to the high rate of recurrence 
and the risk of postoperative decompensation. 9 Transarterial radioembolization with Y-90 
(TARE Y-90) and transarterial chemoembolization (TACE) are the best therapeutic treatments 
and also most commonly used in patients, who are unable to receive curative treatments. 1,11 
TARE Y-90 and TACE are similar regarding general concepts and techniques. In both 
treatments, the primary goal is to block the blood supply by direct delivery of embolic agents to 
the arteries supplying the liver tumors through a catheter. While TACE utilizes a combination of 
microspheres and chemotherapeutic agents mixed with an oil medium, microspheres loaded with 
radioactive isotope Yttrium 90 are used as embolic agents to deliver radiation to the tumors in 
TARE Y-90. 
OBJECTIVE 
The objective of this systemic review is to determine whether TARE Y-90 is a safer 
treatment option compared to TACE in patients with primary liver cancer (HCC).  
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METHODS 
 
The studies used for this review were selected based on the following criteria. The article 
must be a randomized controlled trial, peer reviewed journal, and published in English after 
2008. All three of the articles in this review were selected through a detailed search of articles 
via the Cochrane, PubMed, and Medline databases. Studies from these selected articles were 
based on importance of outcomes to the patient (Patient-Oriented Evidence that Matters). The 
objective of all three articles was to compare the adverse events in post-treatment of TARE Y-90 
and TACE. Statistics used in these studies included relative risk reduction (RRR), absolute risk 
reduction (ARR), number needed to harm (NNH), and p-values. Key words used in searches 
were “hepatocellular carcinoma”, “primary liver cancer”, “chemoembolization”, 
“radioembolization”, and “adverse events”. Table 1 provides demographic information of all 
articles included.  
In all three studies, patients were randomly selected and divided into two groups. One 
group of patients received TARE Y-90, while the other group of patients received TACE. The 
TARE Y-90 group was required to undergo a two-step treatment. First, all patients received an 
injection of Tc-99 macro-aggregated albumin (Tc-99-MAA) into the hepatic artery. Then, a 
single photon emission computed tomography (SPECT) scan of the whole body was performed 
to detect any radiation distribution to the lungs and/or other visceral organs. 11 Embolization 
using coils, detachable balloons, or vascular plugs, was performed to correct any extrahepatic 
shunting within the abdomen. 1,5,11Adverse events were recorded and compared between the two 
groups after treatments. Inclusive criteria included adults with a diagnosis of intermediate stage 
of HCC and a life expectancy of 3 months or greater, who are not eligible for surgical 
transplantation, resection or ablative techniques.  
Vu,	Radioembolization	and	Chemoembolization	in	HCC	
	
5	
	
Table 1: Demographic & Characteristics of included studies 
 
Study Type # of pts Age 
(yr) 
Inclusion Criteria  Exclusion 
Criteria  
W/D Intervention 
El 
Fouly 1  
(2014) 
RCT n = 42 
(TACE) 
58  
±7 
-Age ³18 years 
-Life expectancy >3 
months 
-Diagnosis of HCC 
made by EASL-AASLD 
criteria  
-Liver cirrhosis with 
good liver functions 
-Good performance 
status  
(PST = 0) 
-Intermediate stage 
(BCLC-B) 
-Absence of evidence of 
vascular invasion or 
suspected extra-hepatic 
disease 
Patients who 
were eligible 
for curative 
treatment such 
as resection, 
transplantation, 
or local 
ablation  
0 Chemoembolization 
was performed 
using 50 mg 
Adriamycin mixed 
with lipiodol and 
followed with gel-
foam 
n = 44 
(Y90) 
66 
±9 
0 Radioembolization 
was performed with 
injection of Tc-99-
MAAand glass-
based microspheres.  
Kolligs 
2 
(2015) 
RCT n = 15 
(TACE) 
67 
±7 
 
-Age ³18 years 
-Diagnosed with 
unresectable HCC 
confirmed by either 
histology/cytology or 
EASL diagnostic criteria  
-Preserved liver function 
-ECOG performance of 
£2 
-Absence of any form of 
vascular invasion or 
extrahepatic spread. 
Patients with 
resectable HCC 
 
Patients with 
significant 
extrahepatic 
uptake on 99m 
Tc-MAA scan 
or >15% 
arteriovenous 
shunting from 
liver to lungs 
0 Chemoembolization 
was performed 
using epirubicin 
50mg/m2, lipiodol, 
and embolic 
microspheres  
n = 13 
(Y90) 
66 
±9 
 
0 Radioembolization 
was performed 0.5-
4 GBq 90Y-resin 
microspheres 
Salem 
3  
(2016) 
RCT n = 21 
(TACE) 
 
62 - 
70 
-Image/biopsy – proven 
HCC by guidelines 
-
Unablatable/unresectable 
disease 
-No vascular invasion 
Child-Pugh A/B 
-Bilirubin £2.0 m/dl  
-AST/ALT £5x upper 
limit of normal  
Infiltrative/bulk 
disease (³70% 
tumor burden) 
- ³50% tumor 
burden with 
albumin <3 
g/dL 
-Cardiac 
comorbidities  
 
0 Chemoembolization 
was performed with 
75 mg/m2 of 
drug/lipiodol 
combination and 
followed with 
embolic 
microspheres 
n = 24 
(Y90) 
58 - 
65 
0 Radioembolization 
was performed with 
120 Gy dose of 
glass microspheres. 
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OUTCOMES MEASURED 
 
The adverse events after the treatment of TARE Y-90 and TACE were the outcome 
measured in all three studies. Each study compared the frequency of adverse events between 
patients in TARE Y-90 group and patients in TACE group. Although there were some variations, 
common adverse events were measured in all three studies including fatigue, abdominal pain, 
ascites, peptic ulcers, nausea, vomiting, fever, infection, constipation, and diarrhea. These 
adverse events were recorded using different methods in all of the studies. Both El Fouly et al. 
study and Kolligs et al. study used the National Cancer Institute (NCI) common toxicity criteria 
version 3 (CTCv3) to record and code adverse events during the active treatment and within 2 
months of any treatment procedure. In addition, 45-item self-report Functional Assessment of 
Cancer Therapy (FACT) Hepatobiliary (FACT-Hep) questionnaire was also utilized to assess the 
adverse events at the baseline and at 6-weekly follow-ups in El Fouly et al. study. In the Salem et 
al. study, Common Terminology Criteria for Adverse Events (CTCAE) version 4 was used to 
record the adverse events. 
RESULTS 
 
In the El Fouly et al. study, a total of 116 patients were randomly divided into two 
groups: one group was treated using TARE Y-90 while the other group was treated using TACE.  
After the screening, 9 (8%) patients in the TARE Y-90 and 21 (19%) patients in the TACE group 
were excluded from the trial. The remaining 86 patients with intermediate stage HCC met the 
inclusion criteria and were treated prospectively in a non-randomized controlled study. In TARE 
Y-90, 44 patients received a two-step treatment, which included a screening test detecting 
radiation distribution to extrahepatic organs and embolization with angiography. Arterial 
embolization was performed using TheraSphere, a type of glass-based microsphere composing of 
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20-30 µm large B-emitting particles. In TACE, 42 patients received a conventional technique 
using 500-700 µm chemo-particles, gel foam, and a combination of 50 mg Adriamycin mixed 
with lipiodol. In both groups, any adverse events within 30 days following any treatments were 
evaluated and recorded. Based on the data in table 2, the number of patients with abdominal pain 
after TACE was much higher compared to the number of patients after TARE Y-90 (85% in 
TACE vs. 5% in TARE Y-90; P <0.001). The most common adverse events (40%) after TARE 
Y-90 treatment was fatigue syndrome. However, it was still significantly less than TACE group 
with 73% patients experiencing fatigue syndrome (P <0.01). While nausea and vomiting was 
reported in 38% of patients after TACE, there was no patients in TARE Y-90 group with the 
same adverse event (P <0.001) 
Table 2: Post-therapy adverse events by El Fouly et al. 1 
Adverse Events TACE, n (%) TARE Y-90, n (%) P-value 
Abdominal pain 35 (83) 2 (5) <0.01 
Fatigue syndrome 30 (73) 18 (40) <0.001 
Nausea/vomiting 16 (38) 0 (0) <0.001 
 
In the study by Kolligs et al., 13 patients were randomly selected to receive TACE Y-90 
treatment, and 15 patients were randomly selected to receive TACE treatment. Similar to El 
Fouly et al. study, patients in TACE Y-90 group were required to go through a two-step 
treatment to minimize visceral shunt. After 14 days of the initial step, all TACE Y-90 patients 
received a single session of arterial embolization using 0.5-5 GBq SIR-Spheres, a commercial Y-
90 microspheres from Sirtex Medical in Sydney, Australia.  In TACE group, 15 patients received 
a combination of 50 mg/ m2 epirubicin and lipiodol in conjunction with 150-300 µm or 300-500 
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µm Embosphere, chemo-particles from Merit Medical. In both groups, adverse events within 2 
months following any treatments were evaluated and recorded. Gastrointestinal (GI) events were 
statistically difference between two groups. As illustrated in table 3, the number of patients 
experiencing GI events after TARE Y-90 was more frequent comparing TACE ((40% in TARE 
Y-90 vs. 8% in TACE; P <0.029). Out of 6 patients with GI adverse events in TARE Y-90 
group, 2 patients were reported with abdominal pain.  
Table 3: Post-therapy adverse events Kolligs et al. 5 
Adverse Events TACE, n (%) TARE Y-90, n (%) P-value 
Gastrointestinal events 1 (8) 6 (40) 0.029 
 
In Salem et al. study, a total of 179 patients with intermediate stage (BCLC A or B) HCC 
were eligible for either TARE Y-90 or TACE. However, only 45 patients met the inclusion 
criteria after screening. Twenty-four patients were randomly selected to receive TARE Y-90, and 
21 patients were randomly selected to receive TACE. Before transarterial embolization, patients 
in TARE Y-90 group underwent angiography and technetium-99m scintigraphy to identify 
extrahepatic perfusion of radiation. Coil embolization was performed if any shunting was 
detected. A median dose of 126 Gy TheraSphere was administered to TARE Y-90 patients 
during the last step of the treatment. In TACE group, 42 patients were treated using a 
drug/lipiodol combination at a maximum dose of 150 mg and followed by transarterial 
embolization using Embospheres. The results from table 4 demonstrated a higher number of 
patients experiencing abdominal pain after TACE than TARE Y-90 (53% in TACE vs. 25% in 
TARE Y-90; P <0.11). However, more patients (88%) in TARE Y-90 were reported with fatigue 
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syndrome than in TACE (63%). Nausea and vomiting occurred in both TACE and TARE Y-90 
groups, but there was no significant difference between two groups.  
Table 4: Post-therapy adverse events by Salem et al. 11 
Adverse Events TACE, n (%) TARE Y-90, n (%) P-value 
Abdominal pain 10 (53) 6 (25) 0.11 
Fatigue syndrome 12 (63) 21 (88) 0.08 
Nausea 8 (42) 7 (29) 0.52 
Vomiting 3 (16) 1 (4) 0.31 
 
Abdominal pain was used to compare the relative risk increase (RRI), absolute risk 
increase (ARI), and number needed to harm (NNH) between the three studies. In order to obtain 
these results, it was essential to find the Experimental Event Rate (EER) and Control Event Rate 
(CER). EER was calculated by using the number of people who was treated with TARE Y-90 
and developed abdominal pain (a) dividing by the sum of (a) and the number of people who were 
treated with TARE Y-90 but did not develop abdominal pain (c), CER was calculated by using 
the number of people who were treated with TACE and developed abdominal pain (b) dividing 
by the sum of (b) and the number of people who were treated with TACE and did not develop 
abdominal pain. As illustrated in table 5, the results of Salem et al. showed NNH was 3.62, 
which indicated that for every 4 patient treated, 1 more patient would experience abdominal pain. 
The results of Kolligs et al. study showed NNH was 3.086, which indicated that for every 3 
patients treated, 1 more patient would experience abdominal pain. The results of El Fouly et al. 
showed NNH was 1.269, which indicated that for every 1 patient treated, 1 more patient would 
experience abdominal pain.  
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Table 5: Results of adverse events - Abdominal pain  
Study RRI (%) ARI (%) NNH 
Salem et al 47.5  27.6 3.62 
Kolligs et al 526.3 32.4 3.086 
El Fouly et al 5.4 78.8 1.269 
 
DISCUSSION 
 
This systemic review of three randomized controlled trials evaluated and compared the 
adverse events in patients with HCC after TACE or TARE Y-90. In the United States, 
embolization using chemo particles is the treatment of choice for patients with intermediate 
HCC, those who are not eligible for liver transplantation, hepatic resection, or ablative 
techniques. In early 2000, a new technique using microspheres with high doses of radiation was 
introduced as a possible therapeutic treatment option for intermediate HCC. Since then, it has 
become one of the most common HCC treatment in both teaching and community hospitals. 
Currently, TheraSphere and SIR-Spheres are the two commercial Y-90 microsphere products 
available on the market. Both TheraSphere and SIR-Spheres are approved by The Food and Drug 
Administration (FDA) for the use in the treatment of unresectable intermediate stage HCC. 
TheraSphere is eligible for reimbursement by Medicare, Medicaid, and majority of commercial 
health insurance plans.  
There were noteworthy limitations within all three randomized controlled trial studies. 
The first limitation was the lack of consistency in adverse events measuring methods between the 
three trials. While both Koligs et al. and El Fouly et al. studies used the NCI common toxicity 
criteria version 3 (CTCv3), the adverse events in the study by Salem et al. was recorded by 
CTCAEv4.0. Second limitation involved the variability in dosages, types of chemotherapy 
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agents as well as the sizes of chemo particles used in TACE. Although lipiodol was used as a 
radiopaque contrast agent in all three studies, there was a discrepancy between these studies. In 
El Fouly et al. study, patients in TACE group received a combination of 50 mg Adriamycin 
mixed with lipiodol, gel foam, and 500-700 µm chemo embolizing particles. On the other hand, 
TACE patients in the study by Kolligs et al. received a combination of 50 mg/ m2 epirubicin 
mixed with lipiodol, and 150-300 µm or 300-500 µm chemo embolizing particles. Even though 
both Epirubicin and Adriamycin are members of the same chemotherapy class called 
anthracyclines, they have different chemical structures, and thus they yield distinctive side 
effects 3. In Salem et al study, the name of chemotherapy agent was not mentioned.  
CONCLUSION 
 
Based on this systemic review, it is difficult to conclude whether radioembolization is a 
safer treatment than chemoembolization in patients with HCC due to the highly complex nature 
of the disease. Symptoms such as fatigue, abdominal pain, nausea, and vomiting are commonly 
presented in HCC patients at the time of diagnoses. It is not possible to identify whether these 
symptoms adverse events of the treatments or symptoms of HCC.  
All three randomized controlled studies indicate that both TARE Y-90 and TACE could 
cause adverse events in HCC patients. Two out of three randomized controlled studies suggest 
that the frequency of adverse events between TARE Y-90 and TACE are not significantly 
different. The results of the third study demonstrate that TARE-90 is more superior than TACE 
regarding safety. Overall, both TARE Y-90 and TACE are good treatment of choice for patients 
with unresectable HCC.  It is important to focus on the patient profile when selecting an 
appropriate treatment. Future studies are warranted to larger studies and establish a standard 
method to measure adverse events in post treatment.
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